GIP: how this gut hormone works and why researchers study it

GIP at a glance

• What it is: A 42-amino-acid incretin hormone released by K cells in the upper small intestine in response to dietary fat, carbohydrates, and protein. Source

• Main function: It amplifies glucose-stimulated insulin secretion. Its insulin-releasing effect falls as glucose falls, helping protect against hypoglycemia; this does not mean medicines acting on the pathway cannot cause low blood sugar.

• The incretin effect: Together, GIP and GLP-1 account for an estimated 25–70% of the insulin response after meals in healthy people. This gut-to-pancreas contribution is known as the incretin effect. Source

• In type 2 diabetes: GIP’s ability to stimulate insulin secretion is substantially reduced, an important part of the diminished incretin effect.

• Therapeutic relevance: GIP and GLP-1 receptors are the two targets of tirzepatide, sold in the United States as Mounjaro and Zepbound. In the head-to-head SURPASS-2 trial, tirzepatide lowered HbA1c and body weight more than semaglutide 1 mg. This comparison applies to the studied doses and population. Source

• Beyond glucose: GIP receptors have been identified in adipose tissue, bone, cardiovascular tissue, and the brain. Researchers are investigating roles in fat metabolism, bone turnover, and neuroprotection, with different levels of evidence for each.

Many people first encounter GIP in coverage of tirzepatide. In the United States, Mounjaro is used for type 2 diabetes; Zepbound is used for long-term weight management in eligible adults and for moderate-to-severe obstructive sleep apnea in adults with obesity. SURPASS-2 found greater reductions in HbA1c and weight with tirzepatide than with semaglutide 1 mg. GIP is the “G” in its dual mechanism: gastric inhibitory polypeptide, now more commonly called glucose-dependent insulinotropic polypeptide. Tirzepatide activates its receptor alongside the GLP-1 receptor. Understanding the hormone helps explain the mechanisms that might contribute to those clinical results, although the trial cannot isolate each receptor’s contribution. Source

What is GIP?

GIP is a polypeptide hormone containing 42 amino acids and belonging to the secretin-glucagon family. K cells, a type of enteroendocrine cell concentrated in the duodenum and proximal jejunum, release it after nutrients enter the upper small intestine. Dietary fat, carbohydrates, and protein all stimulate release. Its structure and role as an incretin are well established; research now ranges from the cells that produce it to medicines that act on its receptor. Source Source

Discovery and history

Researchers purified GIP from pig small intestine in the early 1970s and reported its complete amino acid sequence in 1971. The original name, “gastric inhibitory polypeptide,” reflected the idea that its main job was to suppress stomach acid secretion. That turned out to be a relatively minor role. Work during the following decades, including the 1980s and 1990s, established its importance in amplifying insulin secretion after meals in a glucose-dependent manner. The alternative name, “glucose-dependent insulinotropic polypeptide,” preserves the abbreviation while describing that function more accurately. Source

How GIP is made and released

K cells make a larger prepro-GIP precursor, which enzymes process into the active 42-amino-acid hormone. These cells are most abundant in the duodenum and proximal jejunum, well placed to detect nutrients arriving from the stomach. Glucose, long-chain fatty acids, and large neutral amino acids are strong signals for release. After secretion, GIP enters the portal circulation and can reach GIP receptors on pancreatic beta cells. Active GIP has a circulating half-life of about 5–7 minutes. Dipeptidyl peptidase-4, or DPP-4, removes its first two amino acids to form GIP(3–42), a shortened form without the intact hormone’s insulin-stimulating activity. Source

GIP receptors and signaling

The GIP receptor is a G protein-coupled receptor. Activation stimulates adenylyl cyclase, increasing the intracellular messenger cAMP. In pancreatic beta cells, cAMP signals through PKA and Epac pathways to amplify glucose-stimulated insulin secretion. Glucose dependence matters: when glucose is low, the insulin-releasing effect is substantially weaker. This reduces the tendency of physiological GIP signaling to push fasting glucose too low. It is a feature of incretin biology, not a guarantee against hypoglycemia during drug treatment. Source

GIP’s role in the incretin effect

The incretin effect is the greater insulin response to oral glucose than to intravenous glucose when blood glucose levels are matched. It provides the clearest physiological setting for understanding GIP. In healthy people, GIP and GLP-1 help the pancreas release insulin after eating. GIP and insulin concentrations follow similar daily patterns, rising after meals. Whether GIP mainly affects insulin or glucagon secretion depends on the glucose concentration at the time. Source Source Source

GIP’s two-way role in glucose regulation

Both GLP-1 and GIP affect glucagon in a glucose-dependent way, but their effects differ. GLP-1 generally suppresses glucagon when glucose is elevated, whereas GIP can increase it during fasting and at lower glucose concentrations. In healthy people, GIP stimulates pancreatic alpha cells under those conditions, supporting the counterregulatory response. At high glucose, its insulin-releasing effect predominates and its glucagon effect is weaker. This distinction helps explain why dual GIP/GLP-1 agonists can affect glucagon differently from GLP-1 agonists alone. Source Source Source

GIP in type 2 diabetes: the incretin defect

In type 2 diabetes, GIP’s acute ability to stimulate insulin secretion is markedly reduced. GIP can still be released, but the pancreatic response is weaker for reasons that are not fully explained. This is an important component of the diminished incretin effect. A reduced incretin effect is also associated with obesity, although the relationship does not establish which change comes first. The comparison with GLP-1 matters therapeutically: pharmacological GLP-1 stimulation can retain substantial glucose-lowering activity in type 2 diabetes, helping explain the effectiveness of GLP-1 receptor agonists used alone. Historically, the weak response to native GIP made GIP receptor agonism alone seem an unpromising treatment. That historical view should not be confused with a conclusion about every modern, long-acting GIP drug. Source Source Source Source

How receptor desensitization might contribute

Sustained stimulation can make a receptor less responsive. It may become disconnected from its signaling machinery, move inside the cell, or be produced in smaller amounts. Circulating GIP is often normal or elevated in obesity and diabetes, and chronic receptor desensitization has been observed in rodent and cell models. This is a plausible contributor to impaired signaling, not a complete, established explanation for the human incretin defect. Source Source

Other conditions with altered GIP signaling

Diabetes and obesity are not the only settings in which GIP regulation can change:

• Food-induced Cushing syndrome: In certain adrenal disorders, the rise in GIP after a meal can stimulate cortisol release even when ACTH is low. Source

• Cystic fibrosis-related diabetes: A weakened insulin response to GIP has been reported in cystic fibrosis, particularly with pancreatic insufficiency. Source

• Insulinoma and other neuroendocrine tumors: GIP overproduction and increased receptor expression have been reported, while the expected insulin-releasing response may be absent in many insulinoma cases. Source

• Chronic kidney disease: Reduced renal clearance can raise circulating GIP. A higher concentration by itself does not establish an additional biological effect. Source

GIP compared with GLP-1

Both are gut-derived incretin polypeptide hormones, but their cellular origins, receptor distribution, and downstream effects differ. Those differences underpin the rationale for activating both receptors with tirzepatide. Source

Feature	GIP	GLP-1
Cellular origin	K cells concentrated in the duodenum and proximal jejunum, in the upper small intestine	L cells, especially in the distal small intestine and colon, though also present more proximally
Amino acid length	42 amino acids	The active GLP-1(7–36) amide form has 30 amino acids; another active form is GLP-1(7–37)
Release and breakdown	Released within minutes of nutrient intake; often peaks 30–60 minutes after a meal; active plasma half-life about 5–7 minutes	Also released within minutes of nutrient intake; inactivated by DPP-4 more rapidly than GIP
Effect on glucagon	Can increase glucagon in a glucose-dependent manner, especially at low glucose	Generally suppresses glucagon when glucose is elevated; does not abolish the counterregulatory response to hypoglycemia
Gastric emptying	Does not substantially slow gastric emptying	Slows gastric emptying, helping blunt the glucose rise after meals and contributing to early fullness
Appetite and satiety	Animal studies show effects on feeding; early human studies of long-acting selective agonists suggest effects on weight and appetite, while native GIP’s everyday role remains uncertain	Established effects on satiety and food intake through neural pathways, including hypothalamic and hindbrain signaling
Adipose tissue	Supports post-meal triglyceride storage and can affect local adipokine signaling	Limited direct adipose-tissue effects; weight reduction is largely related to reduced food intake and satiety
Type 2 diabetes	Acute insulin-releasing response to native GIP is substantially impaired	Pharmacological insulin-releasing activity is relatively preserved, allowing GLP-1 receptor agonists to work as monotherapy

Source

Source

Source

Source

Source

Source

Tirzepatide’s rationale is that the two receptors may offer complementary effects. GLP-1 contributes to satiety and delayed gastric emptying; GIP may add effects through pancreatic, neural, and adipose-tissue pathways. Bone signaling is biologically interesting but is not an established explanation for tirzepatide’s weight loss. Completed SURPASS-2 results showed greater HbA1c and weight reductions than semaglutide 1 mg. That supports the clinical effectiveness of this dual agonist, without proving how much of the difference comes from each receptor. Source Source

GIP’s effects extend beyond insulin secretion

Identifying GIP receptors outside the pancreas has broadened our understanding of the hormone. A receptor’s presence suggests where a signal may act; demonstrating a useful treatment effect requires additional evidence.

Adipose tissue and fat metabolism

GIP signaling helps promote triglyceride storage in adipose tissue after meals and influences lipid metabolism more broadly. Receptors have been identified in adipose tissue, although detailed mapping places much of the receptor expression in nonfat cells such as pericytes and mesothelial cells within white adipose tissue. Receptor location varies with tissue, species, and measurement method. In genetically modified mice, deletion of the GIP receptor can protect against fat accumulation through changes in energy expenditure and lipid metabolism. These findings explain why researchers study GIP in obesity-related metabolic disease; they do not show that ordinary post-meal GIP secretion inevitably causes obesity. Source Source Source Source Source

GIP, appetite, and the gut-brain connection

GIP receptors are found in several brain regions. In mice, activation of hypothalamic GIP-receptor neurons can acutely reduce food intake, while neurons in the dorsal vagal complex appear to influence energy balance. The contribution of naturally released GIP to human appetite remains less clear. Source

Human pharmacology is beginning to clarify the picture. A phase 1 randomized study of the long-acting selective GIP agonist LY3537021 enrolled 85 healthy participants and people with type 2 diabetes. It found dose-related weight reductions and reports of reduced appetite or early fullness; fasting glucose improvements were transient rather than consistently sustained. These preliminary results support a possible contribution of GIP receptor activation to weight regulation, but the modified drug is not equivalent to the short-lived hormone released after a meal. Source

Bone metabolism

GIP affects bone as well as glucose metabolism. Experimental work shows effects on osteoblasts and bone formation, and human studies show suppression of bone-resorption markers. That fits the observation that bone-resorption markers fall after meals, when GIP secretion rises. In a small study of healthy men, blocking the GIP receptor weakened GIP’s effects on bone-turnover markers. A separate study found that endogenous GIP contributed to post-meal suppression of resorption, without a detectable change in the formation marker P1NP between interventions. These are useful physiological findings; they do not establish fracture prevention or a bone-building treatment. Tirzepatide’s long-term skeletal effects, and the contribution of its GIP component, remain research questions. Source Source Source

Cardiovascular and neuroprotective effects

Low levels of GIP receptor expression have been reported in cardiomyocytes and cardiac pericytes. Preclinical work suggests possible protective cardiovascular effects, including actions relevant to blood vessels and atherosclerosis. Brain research offers another promising direction: GIP has shown neuroprotective effects in animal models, including reduced ferroptosis, a form of iron-dependent cell death, through Epac/Rap1 signaling in mouse and cell models. These findings generate hypotheses for treatment. Clinical benefits from a multi-receptor medicine cannot by themselves establish that isolated GIP signaling protects the human heart or brain. Source Source Source Source Source

Can GIP be measured in blood?

Yes, although measurement belongs mainly to research rather than routine care. Commercial ELISA assays can measure plasma GIP. Assays designed to be specific for GIP distinguish it from GLP-1 and GLP-2, but their validation and the molecular form they detect matter. Antibodies targeting the N-terminal region measure intact active GIP(1–42); C-terminal assays measure total GIP, including truncated forms. Because DPP-4 continues converting active hormone into GIP(3–42), sample collection and processing affect the result. A total concentration is not a direct measure of active receptor signaling or a stand-alone measure of how much hormone the gut secretes. Source

GIP and tirzepatide: the clinical evidence

Tirzepatide is a major clinical application of GIP research. Its dual-receptor mechanism produced better HbA1c and weight outcomes than semaglutide 1 mg in SURPASS-2. Pooled diabetes trials also found greater HbA1c reductions than the studied comparators, including GLP-1 receptor agonists. In a weight-loss meta-analysis, the pooled differences from placebo were 7.7 kg, 11.6 kg, and 11.8 kg for the studied 5 mg, 10 mg, and 15 mg tirzepatide groups, respectively. These are average between-group differences across trials, not guaranteed individual losses. Results depend on dose, population, comparator, and follow-up. In the United States, Mounjaro is approved for type 2 diabetes, while Zepbound has indications for long-term weight management and moderate-to-severe obstructive sleep apnea in adults with obesity. How much of tirzepatide’s advantage comes specifically from GIP receptor activation remains an active mechanistic question. Source Source Source Weight-loss meta-analysis SURPASS-2 trial

Native GIP and long-acting medicines should not be treated as interchangeable. A 2026 randomized study in 61 people with type 2 diabetes tested six weeks of continuous native GIP infusion, alone or added to semaglutide. It did not demonstrate the prespecified improvement in mean glucose; dropouts limited firm conclusions about GIP alone. That finding sits alongside, rather than cancels out, the positive tirzepatide results and preliminary selective-agonist findings. The molecules, exposures, and study designs differ. Source

Why researchers also study GIP blockade

One apparent paradox is that both activating and blocking the GIP receptor are being investigated for weight management. Sustained activation can desensitize a receptor in some experimental settings, making parts of its behavior resemble blockade. This is one possible explanation, not a settled account of every drug effect. Elevated GIP and insulin in some obesity settings have also motivated antagonist research. Selective GIP receptor antagonists have been infused into healthy volunteers as physiological research tools. Source Source

There is now human treatment evidence for a combined approach: a 2025 phase 2 trial found substantial weight loss with maridebart cafraglutide, which combines GIP receptor antagonism with GLP-1 receptor agonism. Gastrointestinal adverse events were common. This supports continued investigation of the combination; it does not show that GIP blockade alone caused the benefit or establish the long-term balance of benefits and risks. Source

What weaker GIP signaling means for metabolic health

In type 2 diabetes, GIP can still be secreted while its insulin-stimulating effect is substantially weakened. This diminished incretin response contributes to impaired glucose regulation after meals and is an important physiological difference from healthy glucose handling. Understanding how fasting glucose, meal-related insulin release, and longer-term glycemia interact gives useful context for familiar metabolic tests.

Fasting insulin, fasting glucose, and HbA1c can describe aspects of metabolism before or during treatment. They do not directly measure the incretin effect or isolate the GIP signaling pathway.

Which lab measurements add context?

Direct GIP measurement is not standard clinical practice. Familiar metabolic markers describe aspects of glucose and fat metabolism influenced by many processes, including insulin and incretin signaling. They are not a recommended “GIP panel.”

• Fasting insulin: Reflects circulating insulin under fasting conditions, influenced by secretion and clearance. Higher concentrations can be consistent with insulin resistance, but do not identify a GIP defect and are not a universal starting test for this pathway.

• Fasting glucose: Provides a baseline measure of glucose regulation. GIP’s meal-related amplification of insulin contributes to post-meal glucose handling, but a fasting result cannot quantify that contribution.

• Hemoglobin A1c, or HbA1c: The primary efficacy endpoint in the SURPASS trials. It summarizes average glycemia over roughly three months, integrating many influences on glucose regulation. It is not a specific measure of whether GIP signaling is working normally. Source

• Triglycerides: GIP supports post-meal triglyceride storage in adipose tissue. Elevated fasting triglycerides can reflect several influences, including insulin resistance, liver metabolism, and diet; they cannot establish impaired GIP-to-adipose signaling.

• hs-CRP: A nonspecific inflammatory marker that can add to cardiovascular risk assessment in selected circumstances. It does not directly measure vascular GIP activity or diagnose a GIP-related problem.

Taken together with clinical history, these measurements can help explain glucose regulation and possible insulin resistance. A specific GIP abnormality cannot be read from them alone.

Tirzepatide safety and prescribing information

Tirzepatide, sold as Mounjaro or Zepbound, is a prescription medicine. US labeling carries a boxed warning about thyroid C-cell tumors observed in rats; whether it causes these tumors in humans is unknown. It is contraindicated with a personal or family history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia syndrome type 2 (MEN 2), and with a history of serious hypersensitivity to tirzepatide. It is not recommended during pregnancy. Serious risks include pancreatitis, gallbladder disease, acute kidney injury related to volume depletion, and severe gastrointestinal reactions. Common adverse effects include nausea, vomiting, diarrhea, constipation, abdominal pain, decreased appetite, and injection-site reactions. Hypoglycemia risk increases when treatment is combined with insulin or an insulin secretagogue; glucose-dependent action does not eliminate this risk.

This article provides general information rather than an individual diagnosis or treatment plan. Starting, changing, or stopping prescription treatment requires coordination with your prescribing clinician.

Full prescribing information for tirzepatide and other medicines acting on GLP-1/GIP pathways is available through DailyMed. Source Current Zepbound label

Frequently asked questions

What does gastric inhibitory polypeptide mean?

Gastric inhibitory polypeptide, or GIP, is a 42-amino-acid hormone released by K cells concentrated in the duodenum and proximal jejunum after intake of fat, carbohydrates, and protein. Its main physiological role is to amplify glucose-stimulated insulin secretion from pancreatic beta cells, making it an incretin hormone. Its complete amino acid sequence was reported in 1971 after work with pig small intestine. “Gastric inhibitory” reflects an early emphasis on its relatively minor stomach-acid effect. “Glucose-dependent insulinotropic polypeptide” is now the more informative name for its principal function. Source Source

What does GIP do?

GIP amplifies insulin secretion when glucose is elevated, with a much weaker insulin-releasing effect at low glucose. That provides a physiological safeguard, though it does not make medicines acting on the pathway free of hypoglycemia risk. GIP can also stimulate glucagon during fasting or low glucose, support triglyceride storage in adipose tissue, and affect bone-turnover markers. Together, GIP and GLP-1 account for an estimated 25–70% of the post-meal insulin response in healthy people, the incretin effect. Source

How is GIP different from GLP-1?

Both are incretin hormones that amplify meal-related insulin secretion, but their origins, receptor biology, and other effects differ. GIP comes mainly from K cells in the upper small intestine; GLP-1 comes from L cells distributed through the intestine, especially farther downstream. GIP can raise glucagon at low glucose, whereas GLP-1 suppresses it when glucose is elevated. GLP-1 slows gastric emptying and reduces appetite through neural pathways. GIP does not substantially delay emptying; its normal physiological role in human appetite remains less clear, although preliminary studies of long-acting selective agonists show effects on weight and appetite. In type 2 diabetes, the acute insulin response to native GIP is weakened, while pharmacological GLP-1 activity remains useful. Activating both receptors may provide complementary effects. Source

Is GIP activity impaired in type 2 diabetes?

Yes. GIP can still be released, but its ability to stimulate insulin secretion is substantially reduced. This contributes to the diminished incretin effect and impaired glucose regulation after meals. The mechanisms are incompletely understood, and the response is not identical in every person. Tirzepatide, which activates both GIP and GLP-1 receptors, achieved better glycemic and weight outcomes than the specific GLP-1 comparators studied. That suggests pharmacological activation with a modified drug need not reproduce the weak response to native GIP. It does not establish that all dual agonists outperform every GLP-1 medicine or dose. Source Source

What is tirzepatide, and why does it activate the GIP receptor?

Tirzepatide is an FDA-approved dual GIP/GLP-1 receptor agonist. US brands include Mounjaro for type 2 diabetes and Zepbound for long-term weight management in eligible adults and moderate-to-severe obstructive sleep apnea in adults with obesity. It was designed to engage both incretin receptors, based on the possibility of complementary or synergistic effects. SURPASS-2 showed larger HbA1c and weight reductions than semaglutide 1 mg. A meta-analysis found average weight differences of 7.7–11.8 kg versus placebo across the studied tirzepatide doses; these were pooled trial results, not individual predictions. Nausea, vomiting, and other gastrointestinal effects are common. The US boxed warning concerns thyroid C-cell tumors observed in rats, with unknown relevance to humans; personal or family MTC and MEN 2 are contraindications. DailyMed provides full prescribing information and the complete safety precautions. Source Source Source Source

Does GIP affect fat storage?

Yes. GIP has effects on adipose tissue in addition to its pancreatic actions and helps support triglyceride storage after meals. Receptor-mapping studies indicate that much of the GIP receptor signal in white adipose tissue comes from nonadipocyte cells, including pericytes and mesothelial cells, rather than fat cells themselves. The precise distribution depends on tissue and experimental method. In mice, deleting the GIP receptor has protected against high-fat-diet-induced obesity through changes in energy expenditure and lipid metabolism. Those findings help explain the scientific interest; they are not proof that blocking GIP alone is an established human weight-loss treatment. Source Source Source Source

Does GIP have effects beyond metabolism?

Yes. Receptors have been identified in bone, cardiovascular tissue, and the brain as well as the pancreas. Experimental work supports effects on bone formation, while small human studies show suppression of bone resorption markers and attenuation of that response with GIP receptor blockade. These findings do not yet establish fewer fractures. Brain research includes animal models of Alzheimer’s and Parkinson’s diseases, along with mouse and cell work linking GIP to protection against ferroptosis through Epac/Rap1 signaling. These are promising preclinical mechanisms, not demonstrated treatment benefits for human neurodegenerative disease. Source Source Source

Can GIP levels be tested?

Specialized assays can measure GIP, but this is not a standard clinical test. Fasting insulin, fasting glucose, and HbA1c describe aspects of glucose regulation rather than directly measuring incretin activity. In healthy people, GIP and GLP-1 secretion patterns correlate with insulin across the day, but a familiar metabolic test cannot isolate those hormones’ contribution or diagnose a GIP signaling defect. Source

Sources and evidence

Nauck MA, D’Alessio DA. Tirzepatide, a dual GIP/GLP-1 receptor co-agonist for the treatment of type 2 diabetes with unmatched effectiveness regrading glycaemic control and body weight reduction. Cardiovasc Diabetol. 2022;21(1):169. Publication

Patel T & Launico MV (2025). Physiology, gastric inhibitory peptide. StatPearls Publishing. Publication

McIntosh CH, Widenmaier S, Kim SJ. Glucose-dependent insulinotropic polypeptide (Gastric Inhibitory Polypeptide; GIP). Vitam Horm. 2009;80:409-71. Publication

Brown JC, Dryburgh JR. A gastric inhibitory polypeptide. II. The complete amino acid sequence. II. The complete amino acid sequence. Can J Biochem. 1971;49(8):867-72. Publication

Gautier JF, Fetita S, Sobngwi E, et al. Biological actions of the incretins GIP and GLP-1 and therapeutic perspectives in patients with type 2 diabetes. Diabetes Metab. 2005;31(3 Pt 1):233-42. Publication

Baggio LL, Drucker DJ. Biology of incretins: GLP-1 and GIP. Gastroenterology. 2007;132(6):2131-57. Publication

Orskov C, Wettergren A, Holst JJ. Secretion of the incretin hormones glucagon-like peptide-1 and gastric inhibitory polypeptide correlates with insulin secretion in normal man throughout the day. Scand J Gastroenterol. 1996;31(7):665-70. Publication

Christensen MB. Glucose-dependent insulinotropic polypeptide: effects on insulin and glucagon secretion in humans. Dan Med J. 2016;63(4). Publication

El K, Campbell JE. The role of GIP in α-cells and glucagon secretion. Peptides. 2020;125:170213. Publication

Gautier JF, Choukem SP, Girard J. Physiology of incretins (GIP and GLP-1) and abnormalities in type 2 diabetes. Diabetes Metab. 2008;34 Suppl 2:S65-72. Publication

Opinto G, Natalicchio A, Marchetti P. Physiology of incretins and loss of incretin effect in type 2 diabetes and obesity. Arch Physiol Biochem. 2013;119(4):170-8. Publication

Wolfe MM, Boylan MO, Chin WW. Glucose-Dependent Insulinotropic Polypeptide in Incretin Physiology: Role in Health and Disease. Endocr Rev. 2025;46(4):479-500. Publication

Min T, Bain SC. The Role of Tirzepatide, Dual GIP and GLP-1 Receptor Agonist, in the Management of Type 2 Diabetes: The SURPASS Clinical Trials. Diabetes Ther. 2021;12(1):143-157. Publication

Thondam SK, Cuthbertson DJ, Wilding JPH. The influence of Glucose-dependent Insulinotropic Polypeptide (GIP) on human adipose tissue and fat metabolism: Implications for obesity, type 2 diabetes and Non-Alcoholic Fatty Liver Disease (NAFLD). Peptides. 2020;125:170208. Publication

Kagdi S, Lyons SA, Beaudry JL. The interplay of glucose-dependent insulinotropic polypeptide in adipose tissue. J Endocrinol. 2024;261(3). Publication

Campbell JE, Beaudry JL, Svendsen B, et al. GIPR Is Predominantly Localized to Nonadipocyte Cell Types Within White Adipose Tissue. Diabetes. 2022;71(5):1115-1127. Publication

Boer GA, Keenan SN, Miotto PM, et al. GIP receptor deletion in mice confers resistance to high-fat diet-induced obesity via alterations in energy expenditure and adipose tissue lipid metabolism. Am J Physiol Endocrinol Metab. 2021;320(4):E835-E845. Publication

Paschetta E, Hvalryg M, Musso G. Glucose-dependent insulinotropic polypeptide: from pathophysiology to therapeutic opportunities in obesity-associated disorders. Obes Rev. 2011;12(10):813-28. Publication

Gasbjerg LS, Hartmann B, Christensen MB, et al. GIP’s effect on bone metabolism is reduced by the selective GIP receptor antagonist GIP(3-30)NH2. Bone. 2020;130:115079. Publication

Helsted MM, Gasbjerg LS, Lanng AR, et al. The role of endogenous GIP and GLP-1 in postprandial bone homeostasis. Bone. 2020;140:115553. Publication

Nauck MA, Quast DR, Wefers J, et al. The evolving story of incretins (GIP and GLP-1) in metabolic and cardiovascular disease: A pathophysiological update. Diabetes Obes Metab. 2021;23 Suppl 3:5-29. Publication

Mori Y, Matsui T, Hirano T, et al. GIP as a Potential Therapeutic Target for Atherosclerotic Cardiovascular Disease-A Systematic Review. Int J Mol Sci. 2020;21(4). Publication

Zhang ZQ, Hölscher C. GIP has neuroprotective effects in Alzheimer and Parkinson’s disease models. Peptides. 2020;125:170184. Publication

Ko J, Jang S, Jang S, et al. Glucose-dependent insulinotropic polypeptide (GIP) alleviates ferroptosis in aging-induced brain damage through the Epac/Rap1 signaling pathway. BMB Rep. 2024;57(9):417-423. Publication

Zhou Q, Lei X, Fu S, et al. Efficacy and safety of tirzepatide, dual GLP-1/GIP receptor agonists, in the management of type 2 diabetes: a systematic review and meta-analysis of randomized controlled trials. Diabetol Metab Syndr. 2023;15(1):222. Publication

de Mesquita YLL, Pera Calvi I, Reis Marques I, et al. Efficacy and safety of the dual GIP and GLP-1 receptor agonist tirzepatide for weight loss: a meta-analysis of randomized controlled trials. Int J Obes (Lond). 2023;47(10):883-892. Publication

Karagiannis T, Avgerinos I, Liakos A, et al. Management of type 2 diabetes with the dual GIP/GLP-1 receptor agonist tirzepatide: a systematic review and meta-analysis. Diabetologia. 2022;65(8):1251-1261. Publication

US Food and Drug Administration. FDA approves first medication for obstructive sleep apnea. December 20, 2024. Publication

DailyMed. National Library of Medicine, National Institutes of Health. Accessed April 23, 2026. Publication

Roell W, Alsina-Fernandez J, Qu H, et al. Long-acting GIPR agonist LY3537021 reduces body weight and fasting blood glucose in patients with T2D: Preclinical development and phase 1 randomized ascending dose studies. Mol Metab. 2026;103:102298. Publication

Frías JP, Davies MJ, Rosenstock J, et al. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes. N Engl J Med. 2021;385(6):503-515. Publication

Helsted MM, Fonnesbech-Wulff C, Schaltz NL, et al. Effects of a 6-week subcutaneous infusion of native GIP alone or as add-on to semaglutide in people with type 2 diabetes: a single-centre, double-blind, parallel-group, randomised, placebo-controlled trial. Lancet Diabetes Endocrinol. 2026;14(7):581-593. Publication

Jastreboff AM, Ryan DH, Bays HE, et al. Once-Monthly Maridebart Cafraglutide for the Treatment of Obesity - A Phase 2 Trial. N Engl J Med. 2025;393(9):843-857. Publication

DailyMed. Zepbound (tirzepatide): US prescribing information. Updated August 28, 2026. Prescribing information